Citation
Dulk, M. den. (2009, September 9). Quality assurance in rectal cancer treatment. Retrieved from https://hdl.handle.net/1887/13966
Version: Corrected Publisher’s Version
License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden
Downloaded from: https://hdl.handle.net/1887/13966
Note: To cite this publication please use the final published version (if
applicable).
Quality assurance in rectal cancer treatment
Marcel den Dulk
© M. den Dulk, 2009
ISBN: 978-90-8559-551-9
Printing of this thesis was financially supported by Duo-Med NV, Covidien, CombiCare BV, Hollister BV, J.E. Jurriaanse Stichting, Amgen BV, B. Braun Medical BV, Coloplast BV, Dansac Nederland, EuroTec BV, EUSA Pharma BV, Fresenius Kabi, GlaxoSmithKline BV, Johnson & Johnson Medical BV, KCI Medical BV, Laprolan BV, MammaPrint, Merck Serano Oncology, Nestlé Healthcare Nutrition, Norgine BV, Novartis Oncology, Nycomed BV, Olympus Nederland BV, Pfizer BV, sanovi-aventis, Taureon, and Roche Nederland BV.
Layout and print: Optima Grafische Communicatie, Rotterdam, The Netherlands
Quality assurance in rectal cancer treatment
Proefschrift
ter verkrijging van
de graad Doctor aan de Universiteit Leiden,
op gezag van de Rector Magnificus prof. mr. P.F. van der Heijden, volgens besluit van het College van Promoties
te verdedigen op woensdag 9 september 2009 klokke 15.00 uur
door
Marcel den Dulk geboren te Leidschendam
in 1976.
prof. dr. C.A.M. Marijnen
Overige leden: prof. dr. R.A.E.M. Tollenaar
prof. dr. T. Wiggers (Universitair Medisch Centrum Groningen, Groningen) dr. H.J.T. Rutten (Catharina-ziekenhuis, Eindhoven)
dr. W.H. Steup (HagaZiekenhuis, Den Haag)
The research described in this thesis was conducted at the department of Surgery of the Leiden University Medical Center, Leiden, the Netherlands and the department of Sta- tistics, European Organisation for Research and Treatment of Cancer. The author of this thesis was supported by a Fellowship from the European Society of Surgical Oncology.
Contents
1 General introduction and outline of the thesis.
In part published as: Quality assurance in surgical oncology: the tale of the Dutch rectal cancer TME trial.
M. den Dulk, C.J.H. van de Velde J Surg Oncol 2008; 97: 5-7.
7
2 Improved overall survival for patients with rectal cancer since 1990: the effects of TME surgery and preoperative radiotherapy.
M. den Dulk, P. Krijnen, C.A.M. Marijnen, H.J.T. Rutten, L.V. van de Poll-Franse, H. Putter, E. Meershoek-Klein Kranenbarg, M.L.E.A. Jansen- Landheer, J.W.W. Coebergh, C.J.H. van de Velde.
Eur J Cancer 2008; 44: 1710-1716.
19
3 Survival of elderly rectal cancer patients not improved: analysis of population-based data on the impact of TME surgery.
H.J.T. Rutten, M. den Dulk, V.E.P.P. Lemmens, G.A.P. Nieuwenhuijzen, P.
Krijnen, M.L.E.A. Jansen-Landheer, L.V. van de Poll Franse, J.W.W. Coebergh, H. Martijn, C.A.M. Marijnen, C.J.H. van de Velde.
Eur J Cancer 2007; 43: 2295-2300.
33
4 Controversies of total mesorectal excision for rectal cancer in elderly patients.
H.J.T. Rutten, M. den Dulk, V.E.P.P. Lemmens, C.J.H. van de Velde, C.A.M.
Marijnen.
Lancet Oncol 2008; 9: 494-501.
47
5 The abdominoperineal resection itself is associated with an adverse outcome: the European experience based on a pooled analysis of five European randomised clinical trials on rectal cancer.
M. den Dulk, H. Putter, L. Collette, C.A.M. Marijnen, J. Folkesson, J. F. Bosset, C. Rödel, K. Bujko, L. Påhlman, C.J.H. van de Velde.
Eur J Cancer 2009; 45: 1175-1183.
65
6 Risk factors for adverse outcome in patients with rectal cancer treated with an abdominoperineal resection in the total mesorectal excision trial.
M. den Dulk, C.A.M. Marijnen, H. Putter, H.J.T. Rutten, G.L. Beets, T. Wiggers, I.D. Nagtegaal, C.J.H. van de Velde.
Ann Surg 2007; 246: 83-90.
81
resection margin not influenced by preoperative treatment. Results from EORTC trial 22921.
M. den Dulk, L. Collette, C.J.H. van de Velde, C.A.M. Marijnen, G. Calais, L.
Mineur, P. Maingon, L. Radosevic-Jelic, A. Daban, J.F. Bosset.
Eur J Cancer 2007; 43: 1821-1828.
8 Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group.
L. Collette, J.F. Bosset, M. den Dulk, F. Nguyen, L. Mineur, P. Maingon, L.
Radosevic-Jelic, M. Piérart, G. Calais.
J Clin Oncol 2007; 25: 4379-4386.
113
9 The association between diverting stomas and symptomatic anastomotic leakage after low anterior resection for rectal cancer.
M. den Dulk, C.A.M. Marijnen, L. Collette, H. Putter, L. Påhlman, J.
Folkesson, J.F. Bosset, C. Rödel, K. Bujko, C.J.H. van de Velde.
Br J Surg 2009, accepted.
129
10 Improved diagnosis and treatment of anastomotic leakage after colorectal surgery.
M. den Dulk, S.L. Noter, E.R. Hendriks, M.A.M. Brouwers, C.H. van der Vlies, R.J. Oostenbroek, A.G. Menon, W.H. Steup, C.J.H. van de Velde.
Eur J Surg Oncol 2009; 35: 420-426.
145
11 A multivariate analysis of limiting factors for stoma reversal in patients with rectal cancer entered into the total mesorectal excision (TME) trial: a retrospective study.
M. den Dulk, M. Smit, K.C.M.J. Peeters, E. Meershoek-Klein Kranenbarg, H.J.T. Rutten, T. Wiggers, H. Putter, C.J.H. van de Velde.
Lancet Oncol 2007; 8: 297-303.
159
12 General discussion 175
Summary 185
Nederlandse samenvatting 193
13 Acknowledgements 203
Curriculum Vitae 205
List of publications 207
